1035688-66-4

Usage

Uses

Used in Pharmaceutical Development:
2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid is used as a potential drug candidate for the treatment of various medical conditions, including cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. Its unique structure and potential pharmacological properties make it a promising candidate for further research and development.
Used in Cardiovascular Disease Treatment:
In the pharmaceutical industry, 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid is used as a potential therapeutic agent for cardiovascular diseases. Its specific structural features may contribute to improved binding affinity and metabolic stability, enhancing its efficacy in treating cardiovascular conditions.
Used in Neurodegenerative Disorder Treatment:
2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid is used as a potential therapeutic agent for neurodegenerative disorders. Its unique structure may offer advantages in targeting specific pathways or receptors involved in the progression of these disorders, providing a new avenue for treatment development.
Used in Inflammatory Condition Treatment:
In the field of inflammatory condition treatment, 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid is used as a potential therapeutic agent. Its structural modifications may enhance its binding affinity and metabolic stability, making it a promising candidate for the development of new drugs to treat inflammatory conditions.
Further research and testing are required to fully understand the pharmacological profile and potential therapeutic uses of 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid, ensuring its safety and efficacy in various medical applications.

Upstream product

• 2942-59-8 2-chloronicotinic acid 
• 1290050-53-1 3,5-difluoro-3'-methoxybiphenyl-4-amine hydrochloride 
• 10365-98-7 3-methoxyphenylboronic acid 

Relevant academic research and scientific papers

PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4 YL)AMINO]NICOTINIC ACID

The present disclosure relates to a process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′biphenyl-4-yl)amino]nicotinic acid.

Amino derivatives for the treatment of proliferative skin disorders

Compositions comprising specific amino derivatives for their use in treating proliferative skin diseases or disorders and the use of specific amino derivatives in such a treatment is disclosed

PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID

This invention is directed to a process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1' biphenyl-4-yl)amino]nicotinic acid, which comprises the steps of: a) providing 3,5-difluoro-3'-methoxybiphenyl-4-amine, b) preparing and isolating an aminium salt of the 3,5-difluoro-3'-methoxybiphenyl- 4-amine, and c) further reacting the aminium salt of 3,5-difluoro-3'-methoxybiphenyl-4-amine obtained in b) to obtain 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4- yl)amino]nicotinic acid.

Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

This invention is directed to a process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid, which comprises the steps of: a) providing 3,5-difluoro-3'-methoxybiphenyl-4-amine, b) preparing and isolating an aminium salt of the 3,5-difluoro-3'-methoxybiphenyl-4-amine, and c) further reacting the aminium salt of 3,5-difluoro-3'-methoxybiphenyl-4-amine obtained in b) to obtain 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid.

AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS

A compound of formula (I) wherein : - one of the groups G1represents a nitrogen atom or a group CRc and the other represents a group CRc; - G2 represents a nitrogen atom or a group CRd; - R1 represents a group selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R2 represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Ra, Rb and Rc independently represent groups selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Rd represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - one of the groups G3 and G4 is a nitrogen atom and the other is a CH group; - M is a hydrogen atom or an pharmaceutically acceptable cation with the proviso that, when at least one of the groups Ra and Rb represent a hydrogen atom and G2 is a group CRd, then Rd represents a groups selected from C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; and the pharmaceutically acceptable salts and N-oxides thereof.